NGEN.V - NervGen Pharma Corp.

TSXV - TSXV Real Time Price. Currency in CAD
1.7000
0.0000 (0.00%)
At close: 03:21PM EDT
Stock chart is not supported by your current browser
Previous Close1.7000
Open1.7300
Bid1.7000 x 0
Ask1.7300 x 0
Day's Range1.7000 - 1.7300
52 Week Range1.5000 - 2.6000
Volume1,000
Avg. Volume21,212
Market Cap100.659M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.3500
Earnings DateAug 08, 2023 - Aug 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
  • Newsfile

    NervGen Pharma Extends the Expiry Date of Certain Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options (the "Options") granted to a consultant of the Company on April 23, 2021 and July 16, 2021, such that the terms of the Options shall ...

  • Newsfile

    NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - May 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company, exercisable at a price of $1.61 per share for a period of five years and that vest equally every three months over ...

  • Newsfile

    NervGen Pharma Announces Results of Annual General Meeting of Shareholders

    All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on May 17, 2023. "We appreciate the support demonstrated by our shareholders at this AGM," stated Bill Radvak, NervGen

  • Newsfile

    NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291

    Phase 1 clinical trial dosing completedPhase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023Cash and investments of $18.0 million as of March 31, 2023Vancouver, British Columbia--(Newsfile Corp. - May 15, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today re

  • Newsfile

    NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting

    Phase 1b/2a trial expected to commence in Q3 2023First readout anticipated in 2024Vancouver, British Columbia--(Newsfile Corp. - April 13, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming American Spinal Injury Association (ASIA) 50th Annual Scientific Meeting being held on April 17-19,

  • Newsfile

    NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer

    Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. Michael Kelly to the position of President & CEO effective April 10, 2023. Mr. Kelly has also been appointed as a member of NervGen's Board of Directors. "We are very excited ...

  • Newsfile

    NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023

    Equity proceeds of CA$22M+ raised during 2022 fiscal yearPhase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoingPhase 1b/2a clinical trial of NVG-291 to include individuals with chronic and subacute spinal cord injuriesVancouver, British Columbia--(Newsfile Corp. - March 30, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the tr

  • Newsfile

    NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

    Completed NVG-291 dosing of subjects in Phase 1 clinical trialPhase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023NVG-291 has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination and plasticity Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biote

  • Newsfile

    NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office

    Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University. NervGen has an exclusi

  • Newsfile

    NervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results

    Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal femalesU.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to commenceGlenn Ives appointed as Lead Independent DirectorVancouver, British Columbia--(Newsfile Corp. - November 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a cl

  • Newsfile

    NervGen Engages Cloutier Consulting to Provide Media Relations Services

    Vancouver, British Columbia--(Newsfile Corp. - October 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Cloutier Consulting, a Texas based public relations specialty agency, to provide media relations and related services for the Company.Cloutier Consulting was engaged for an initial term of one year. Clo

  • Newsfile

    NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

    Dose(s) to be tested in bridging cohorts of males and premenopausal females resulted in significant functional improvements in animal models of nervous system damageNervGen has completed enrollment of third and final multiple ascending dose cohort of postmenopausal womenVancouver, British Columbia--(Newsfile Corp. - October 25, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for t

  • Newsfile

    NervGen Pharma Presenting at Upcoming Scientific Meetings

    AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETINGEUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS Vancouver, British Columbia--(Newsfile Corp. - October 20, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting posters at two upcoming scientific meetings - the 147th American Neurological Association (ANA) a

  • Newsfile

    NervGen Pharma Awarded up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

    The $1.5 million award is to evaluate the ability of NervGen's NVG-291-R to accelerate and enhance restoration of function following peripheral nerve injury (PNI)The research is to support a potential game changing therapeutic approach to restore function for US military service members and the estimated 20+ million Americans suffering from PNI There are currently no effective regenerative pharmaceuticals to enhance recovery in PNI Vancouver, British Columbia--(Newsfile Corp. - October 12, 2022)

  • Newsfile

    NervGen Pharma Announces Leadership Transition

    Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the Board of Directors, appointed interim President Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Directors; will serve as a strategic advisor for a transition periodVancouver, British Columbia--(Newsfile Corp. - September 22, 2022) - NervGen Pharma Corp. (OTCQX: NGENF) (TSXV: NGEN), a clinical stage biotech company ...

  • Newsfile

    NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development

    Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repairDr. Lukashev brings over 20 years' experience including work at Biogen and the ALS Therapy Development Institute Vancouver, British Columbia--(Newsfile Corp. - September 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, is pleased t

  • News Direct

    Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?

    By Paul Henley, Benzinga

  • Newsfile

    NervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting

    Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a poster at the upcoming Military Health System Research Symposium (MHSRS) on September 12-15, 2022 and will also present an oral presentation at the 61st International Spinal Cord Society (ISCoS) Annual Scientific Mee

  • Newsfile

    NervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Update

    Cash position enhanced by over $22 million due to private placement and exercise of warrants and optionsDosing in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial ongoingDiscussions ongoing with FDA regarding partial clinical holdUpdate provided on developments with US Government related to non-dilutive funding in spinal cord injury and traumatic brain injury Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (O

  • Newsfile

    NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conference

    Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer's disease clinical trial at the 2022 Alzheimer's Association International Conference (AAIC) on August 3, 2022. NervGen's Chief Medical Officer, Dr. Daniel Mikol, will present a poster sum

  • Business Wire

    NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University

    VANCOUVER, British Columbia, July 28, 2022--NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), is pleased to announce the University of Cincinnati and Case Western Reserve University (CWRU) have published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke, even when treatment was initiated up to 7

  • Newsfile

    NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non-brokered private placement (the "Private Placement") of 10,150,000 units of the Company at a price of US$1.50 per unit (the "Unit Price"), for aggregate gross proceeds to the

  • Newsfile

    NervGen Pharma Provides Update on Closing of Private Placement

    NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has received conditional approval from the TSX Venture Exchange ("TSXV") for its previously announced US$15,225,000 non-brokere

  • Newsfile

    NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement

    NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - June 30, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, is pleased to announce that it has entered into binding subscription agreements for a non-brokered private placement (the "Private Placement") of